F-18-THK-5351
Phase 2Small molecule
F-18-THK-5351 is one of 7 small molecule programs targeting Neurodegeneration. It is currently in Phase 2.
1
Indications
2
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Neurodegeneration
#DrugCompanyPhaseTrials
1Campath
GGenzyme, a Sanofi Company
Approved
Dayvigo
EisaiPhase 2
Ferriprox
Chiesi Farmaceutici S.p.A.Phase 2
F-18
BayerPhase 2
Namenda
AbbViePreclinical
Intropin
PfizerPreclinical
F-18-THK-5351
CChang Gung Memorial Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Alzheimer's Disease1 trial
Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )
Completed·—·Phase 1·NCT02686216·24 enrolled
Neurodegeneration1 trial
Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK)
Completed·—·Phase 2·NCT03430869·59 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F-18-THK-5351. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CChang Gung Memorial Hospital